Potent acid inhibition by vonoprazan in comparison with esomeprazole, with reference to CYP2C19 genotype

Alimentary Pharmacology and Therapeutics

Volumn 43, Issue 10, 2016, Pages 1048-1059

  Kagami, T ^a   Sahara, S ^a   Ichikawa, H ^a   Uotani, T ^a   Yamade, M ^a   Sugimoto, M ^a   Hamaya, Y ^a   Iwaizumi, M ^a   Osawa, S ^a   Sugimoto, K ^a   Miyajima, H ^a   Furuta, T ^a  

^a HAMAMATSU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450 2C19; ESOMEPRAZOLE; VONOPRAZAN; 1-(5-(2-FLUOROPHENYL)-1-(PYRIDIN-3-YLSULFONYL)-1H-PYRROL-3-YL)-N-METHYLMETHANAMINE; PROTON PUMP INHIBITOR; PYRROLE DERIVATIVE; SULFONAMIDE;

ADULT; ARTICLE; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIGESTIVE TRACT PARAMETERS; DRUG EFFECT; DRUG EFFICACY; DRUG POTENCY; FEMALE; GASTRIC PH MONITORING; GENOTYPE; HUMAN; JAPANESE (PEOPLE); MALE; PHARMACOGENETICS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; VOLUNTEER; COMPARATIVE STUDY; DOSE RESPONSE; DRUG ADMINISTRATION; GENETICS; JAPAN; PH; SECRETION (PROCESS); STOMACH ACID;

ADULT; CROSS-OVER STUDIES; CYTOCHROME P-450 CYP2C19; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; ESOMEPRAZOLE; FEMALE; GASTRIC ACID; GENOTYPE; HUMANS; HYDROGEN-ION CONCENTRATION; JAPAN; MALE; PROTON PUMP INHIBITORS; PYRROLES; SULFONAMIDES;

EID: 84961266527     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/apt.13588     Document Type: Article

References (63)

1. Walsh JH, Peterson WL,. The treatment of Helicobacter pylori infection in the management of peptic ulcer disease. N Engl J Med 1995; 333: 984-91.
2. Furuta T, Shirai N, Watanabe F, et al,. Effect of cytochrome P4502C19 genotypic differences on cure rates for gastroesophageal reflux disease by lansoprazole. Clin Pharmacol Ther 2002; 72: 453-60.
3. Furuta T, Sagehashi Y, Shirai N, et al,. Influence of CYP2C19 polymorphism and Helicobacter pylori genotype determined from gastric tissue samples on response to triple therapy for H. pylori infection. Clin Gastroenterol Hepatol 2005; 3: 564-73.
4. Sugimoto M, Furuta T, Shirai N, et al,. Evidence that the degree and duration of acid suppression are related to Helicobacter pylori eradication by triple therapy. Helicobacter 2007; 12: 317-23.
5. Sohn DR, Kobayashi K, Chiba K, Lee KH, Shin SG, Ishizaki T,. Disposition kinetics and metabolism of omeprazole in extensive and poor metabolizers of S-mephenytoin 4'-hydroxylation recruited from an Oriental population. J Pharmacol Exp Ther 1992; 262: 1195-202.
6. Chiba K, Kobayashi K, Manabe K, Tani M, Kamataki T, Ishizaki T,. Oxidative metabolism of omeprazole in human liver microsomes: cosegregation with S-mephenytoin 4'-hydroxylation. J Pharmacol Exp Ther 1993; 266: 52-9.
7. Pearce RE, Rodrigues AD, Goldstein JA, Parkinson A,. Identification of the human P450 enzymes involved in lansoprazole metabolism. J Pharmacol Exp Ther 1996; 277: 805-16.
8. Sohn DR, Kwon JT, Kim HK, Ishizaki T,. Metabolic disposition of lansoprazole in relation to the S-mephenytoin 4'-hydroxylation phenotype status. Clin Pharmacol Ther 1997; 61: 574-82.
9. Chang M, Tybring G, Dahl ML, et al,. Interphenotype differences in disposition and effect on gastrin levels of omeprazole-suitability of omeprazole as a probe for CYP2C19. Br J Clin Pharmacol 1995; 39: 511-8.
10. Kubota T, Chiba K, Ishizaki T,. Genotyping of S-mephenytoin 4'-hydroxylation in an extended Japanese population. Clin Pharmacol Ther 1996; 60: 661-6.
11. Ishizaki T, Horai Y,. Review article: cytochrome P450 and the metabolism of proton pump inhibitors-emphasis on rabeprazole. Aliment Pharmacol Ther 1999; 13 (Suppl. 3): 27-36.
12. Kurzawski M, Gawronska-Szklarz B, Wrzesniewska J, Siuda A, Starzynska T, Drozdzik M,. Effect of CYP2C19∗17 gene variant on Helicobacter pylori eradication in peptic ulcer patients. Eur J Clin Pharmacol 2006; 62: 877-80.
13. Sugimoto K, Uno T, Yamazaki H, Tateishi T,. Limited frequency of the CYP2C19∗17 allele and its minor role in a Japanese population. Br J Clin Pharmacol 2008; 65: 437-9.
14. Sugimoto M, Furuta T, Shirai N, et al,. Different dosage regimens of rabeprazole for nocturnal gastric acid inhibition in relation to cytochrome P450 2C19 genotype status. Clin Pharmacol Ther 2004; 76: 290-301.
15. Sugimoto M, Furuta T, Shirai N, et al,. Comparison of an increased dosage regimen of rabeprazole versus a concomitant dosage regimen of famotidine with rabeprazole for nocturnal gastric acid inhibition in relation to cytochrome P450 2C19 genotypes. Clin Pharmacol Ther 2005; 77: 302-11.
16. Shirai N, Furuta T, Moriyama Y, et al,. Effects of CYP2C19 genotypic differences in the metabolism of omeprazole and rabeprazole on intragastric pH. Aliment Pharmacol Ther 2001; 15: 1929-37.
17. Furuta T, Ohashi K, Kosuge K, et al,. CYP2C19 genotype status and effect of omeprazole on intragastric pH in humans. Clin Pharmacol Ther 1999; 65: 552-61.
18. Saitoh T, Otsuka H, Kawasaki T, et al,. Influences of CYP2C19 polymorphism on recurrence of reflux esophagitis during proton pump inhibitor maintenance therapy. Hepatogastroenterology 2009; 56: 703-6.
19. Kawamura M, Ohara S, Koike T, et al,. Cytochrome P450 2C19 polymorphism influences the preventive effect of lansoprazole on the recurrence of erosive reflux esophagitis. J Gastroenterol Hepatol 2007; 22: 222-6.
20. Kawamura M, Ohara S, Koike T, et al,. The effects of lansoprazole on erosive reflux oesophagitis are influenced by CYP2C19 polymorphism. Aliment Pharmacol Ther 2003; 17: 965-73.
21. Furuta T, Shirai N, Takashima M, et al,. Effect of genotypic differences in CYP2C19 on cure rates for Helicobacter pylori infection by triple therapy with a proton pump inhibitor, amoxicillin, and clarithromycin. Clin Pharmacol Ther 2001; 69: 158-68.
22. Sugimoto M, Shirai N, Nishino M, et al,. Comparison of acid inhibition with standard dosages of proton pump inhibitors in relation to CYP2C19 genotype in Japanese. Eur J Clin Pharmacol 2014; 70: 1073-8.
23. Hassan-Alin M, Andersson T, Niazi M, Rohss K,. A pharmacokinetic study comparing single and repeated oral doses of 20 mg and 40 mg omeprazole and its two optical isomers, S-omeprazole (esomeprazole) and R-omeprazole, in healthy subjects. Eur J Clin Pharmacol 2005; 60: 779-84.
24. Sahara S, Sugimoto M, Uotani T, et al,. Twice-daily dosing of esomeprazole effectively inhibits acid secretion in CYP2C19 rapid metabolisers compared with twice-daily omeprazole, rabeprazole or lansoprazole. Aliment Pharmacol Ther 2013; 38: 1129-37.
25. Parsons ME, Keeling DJ,. Novel approaches to the pharmacological blockade of gastric acid secretion. Expert Opin Investig Drugs 2005; 14: 411-21.
26. Drug approval review for vonoprazan fumarate (in Japanese). The Pharmaceuticals and Medical Devices Agency of Japan 2014. Available at: http://www.pmda.go.jp/. Accessed 24 February 2015.
27. The interview form for vonoprazan fumarate (Takecab tablets 10 mg and 20 mg) ver. 3 (in Japanese). Takeda Pharmaceutical Company Limited 2015. Available at: http://www.takeda.co.jp/.
28. Prescribing information of Takecab tablets 10 mg and 20 mg ver 6 (in Japanese). Takeda Pharmaceutical Company Limited 2015. Available at: http://www.takeda.co.jp/.
29. Scott DR, Munson KB, Marcus EA, Lambrecht NW, Sachs G,. The binding selectivity of vonoprazan (TAK-438) to the gastric H(+), K(+) -ATPase. Aliment Pharmacol Ther 2015; 42: 1315-26.
30. Srinivas N,. Letter: vonoprazan, a long-lasting acid suppressor of the gastric H+, K + -ATPases with-implications for renal H+, K + -ATPases. Aliment Pharmacol Ther 2016; 43: 442-3.
31. Hori Y, Imanishi A, Matsukawa J, et al,. 1-[5-(2-Fluorophenyl)-1-(pyridin-3-ylsulfonyl)-1H-pyrrol-3-yl]-N-methylmethanamin e monofumarate (TAK-438), a novel and potent potassium-competitive acid blocker for the treatment of acid-related diseases. J Pharmacol Exp Ther 2010; 335: 231-8.
32. Scott D, Weeks D, Melchers K, Sachs G,. The life and death of Helicobacter pylori. Gut 1998; 43 (Suppl. 1): S56-60.
33. Marcus EA, Inatomi N, Nagami GT, Sachs G, Scott DR,. The effects of varying acidity on Helicobacter pylori growth and the bactericidal efficacy of ampicillin. Aliment Pharmacol Ther 2012; 36: 972-9.
34. Scott DR, Weeks D, Hong C, Postius S, Melchers K, Sachs G,. The role of internal urease in acid resistance of Helicobacter pylori. Gastroenterology 1998; 114: 58-70.
35. Jain R, Danziger LH,. The macrolide antibiotics: a pharmacokinetic and pharmacodynamic overview. Curr Pharm Des 2004; 10: 3045-53.
36. Bell NJ, Burget D, Howden CW, Wilkinson J, Hunt RH,. Appropriate acid suppression for the management of gastro-oesophageal reflux disease. Digestion 1992; 51 (Suppl. 1): 59-67.
37. Iinuma K, Ikeda I, Takai M, Yanagawa Y, Kurata K,. Gastrin radioimmunoassay with polyethylene glycol method. Radioisotopes 1982; 31: 350-6.
38. Suzuki S, Komori M, Hirai M, Ureshino N, Kimura S,. Development of a novel, fully-automated genotyping system: principle and applications. Sensors (Basel) 2012; 12: 16614-27.
39. Jenkins H, Sakurai Y, Nishimura A, et al,. Randomised clinical trial: safety, tolerability, pharmacokinetics and pharmacodynamics of repeated doses of TAK-438 (vonoprazan), a novel potassium-competitive acid blocker, in healthy male subjects. Aliment Pharmacol Ther 2015; 41: 636-48.
40. Sakurai Y, Mori Y, Okamoto H, et al,. Acid-inhibitory effects of vonoprazan 20 mg compared with esomeprazole 20 mg or rabeprazole 10 mg in healthy adult male subjects-a randomised open-label cross-over study. Aliment Pharmacol Ther 2015; 42: 719-30.
41. Grayson ML, Eliopoulos GM, Ferraro MJ, Moellering RC Jr,. Effect of varying pH on the susceptibility of Campylobacter pylori to antimicrobial agents. Eur J Clin Microbiol Infect Dis 1989; 8: 888-9.
42. Hunt RH,. pH and Hp-gastric acid secretion and Helicobacter pylori: implications for ulcer healing and eradication of the organism. Am J Gastroenterol 1993; 88: 481-3.
43. Heifets LB, Lindholm-Levy PJ, Comstock RD,. Clarithromycin minimal inhibitory and bactericidal concentrations against Mycobacterium avium. Am Rev Respir Dis 1992; 145: 856-8.
44. Murakami K, Sakurai Y, Shiino M, Funao N, Nishimura A, Asaka M,. Tu1056 A Phase 3, double-blind study of a triple therapy with TAK-438, amoxicillin, and clarithromycin as first line eradication of H. pylori and a triple therapy with TAK-438, Amoxicillin, and metronidazole as second line eradication of H. pylori. Gastroenterology, 146: S-740.
45. Echizen H,. The first-in-class potassium-competitive acid blocker, vonoprazan fumarate: pharmacokinetic and pharmacodynamic considerations. Clin Pharmacokinet 2015; doi: 10.1007/s40262-015-0326-7 [Epub ahead of print].
46. Takeda. Efficacy of TAK-438, Amoxicillin and Clarithromycin in the first line eradication of H. pylori. ClinicalTrialsgov (US National Institutes of Health). Available at: http://www.clinicaltrials.gov/ (NCT01505127).
47. Adachi K, Fujishiro H, Katsube T, et al,. Predominant nocturnal acid reflux in patients with Los Angeles grade C and D reflux esophagitis. J Gastroenterol Hepatol 2001; 16: 1191-6.
48. Ashida K, Sakurai Y, Nishimura A, et al,. Randomised clinical trial: a dose-ranging study of vonoprazan, a novel potassium-competitive acid blocker, vs. lansoprazole for the treatment of erosive oesophagitis. Aliment Pharmacol Ther 2015; 42: 685-95.
49. Brenna E, Waldum HL,. Trophic effect of gastrin on the enterochromaffin like cells of the rat stomach: establishment of a dose response relationship. Gut 1992; 33: 1303-6.
50. Larsson H, Hakanson R, Mattsson H, Ryberg B, Sundler F, Carlsson E,. Omeprazole: its influence on gastric acid secretion, gastrin and ECL cells. Toxicol Pathol 1988; 16: 267-72.
51. Havu N,. Enterochromaffin-like cell carcinoids of gastric mucosa in rats after life-long inhibition of gastric secretion. Digestion 1986; 35 (Suppl. 1): 42-55.
52. Larsson H, Carlsson E, Mattsson H, et al,. Plasma gastrin and gastric enterochromaffinlike cell activation and proliferation. Studies with omeprazole and ranitidine in intact and antrectomized rats. Gastroenterology 1986; 90: 391-9.
53. Carlsson E, Larsson H, Mattsson H, Ryberg B, Sundell G,. Pharmacology and toxicology of omeprazole-with special reference to the effects on the gastric mucosa. Scand J Gastroenterol Suppl 1986; 118: 31-8.
54. Lee H, Hakanson R, Karlsson A, Mattsson H, Sundler F,. Lansoprazole and omeprazole have similar effects on plasma gastrin levels, enterochromaffin-like cells, gastrin cells and somatostatin cells in the rat stomach. Digestion 1992; 51: 125-32.
55. Graham DY, Genta RM,. Long-term proton pump inhibitor use and gastrointestinal cancer. Curr Gastroenterol Rep 2008; 10: 543-7.
56. Robinson M,. Review article: current perspectives on hypergastrinaemia and enterochromaffin-like-cell hyperplasia. Aliment Pharmacol Ther 1999; 13 (Suppl. 5): 5-10.
57. Sheen E, Triadafilopoulos G,. Adverse effects of long-term proton pump inhibitor therapy. Dig Dis Sci 2011; 56: 931-50.
58. Tepes B,. Long-term acid inhibition: benefits and harms. Dig Dis 2011; 29: 476-81.
59. Lundell L, Vieth M, Gibson F, Nagy P, Kahrilas PJ,. Systematic review: the effects of long-term proton pump inhibitor use on serum gastrin levels and gastric histology. Aliment Pharmacol Ther 2015; 42: 649-63.
60. Haga Y, Nakatsura T, Shibata Y, et al,. Human gastric carcinoid detected during long-term antiulcer therapy of H2 receptor antagonist and proton pump inhibitor. Dig Dis Sci 1998; 43: 253-7.
61. Jianu CS, Fossmark R, Viset T, et al,. Gastric carcinoids after long-term use of a proton pump inhibitor. Aliment Pharmacol Ther 2012; 36: 644-9.
62. Jianu CS, Lange OJ, Viset T, et al,. Gastric neuroendocrine carcinoma after long-term use of proton pump inhibitor. Scand J Gastroenterol 2012; 47: 64-7.
63. Ramsjo M, Aklillu E, Bohman L, Ingelman-Sundberg M, Roh HK, Bertilsson L,. CYP2C19 activity comparison between Swedes and Koreans: effect of genotype, sex, oral contraceptive use, and smoking. Eur J Clin Pharmacol 2010; 66: 871-7.